Boehringer Ingelheim is paying $358 million upfront to claim options on up to six antibody-drug conjugates (ADCs) and T cell ...

As an oncologist with more than 25 years of experience across clinical care, research, drug and device development, and ...

Businesses are finding that AI is a great leveller. Organisations with mature digital infrastructures can use AI to unlock ...

Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy, which ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

Hard on the heels of a £1 billion investment package by pharma companies in last week's UK Budget, AbbVie has pledged another ...

The BioInnovation Institute (BII) has expanded a network striving to develop treatments for cardiometabolic diseases and ...

Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in the third quarter, according to chief executive Bill Anderson. The rise in pharma ...

Eli Lilly has added another arrow to the quiver of its new diabetes and weight-loss therapy retatrutide, comprehensively outperforming Novo's rival Ozempic in a head-to-head trial. Results from the ...

Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been recommended for conditional approval in the EU. The EMA's human medicines ...

AbbVie has filed for FDA approval of its T-cell engager (TCE) etentamig in relapsed or refractory multiple myeloma, a key pillar of its strategic expansion into oncology. The drug, described as a ...

UK biotech EnteroBiotix has reported proof-of-concept data for its therapy for irritable bowel syndrome (IBS) based on gut microorganism species collected from healthy, screened donors. The Glasgow, ...